Title : First PARP Inhibitor Ok'd for Breast Cancer.

Pub. Date : 2018 Mar

PMID : 29382645






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The FDA has approved olaparib, a PARP inhibitor, for use in patients with metastatic breast cancer who also carry a germline BRCA1 or BRCA2 mutation. olaparib collagen type XI alpha 2 chain Homo sapiens